ToMoonD personal page - To The Moon

ToMoonD

ToMoonD

No personal profile

67Follow

1Followers

0Topic

0Badge

2021-06-29

$Mind Medicine (MindMed) Inc.(MNMD)$Hdshehejd

2021-06-28

Shuhshsjddds

5 Buffett Stocks to Buy Hand Over Fist for the Second Half of 2021

2021-06-27

Ok nice

Bitcoin falls 8.5% to $31,700

2021-06-22

$Mind Medicine (MindMed) Inc.(MNMD)$Nooo let’s ho

2021-05-26

Hdkeold

2021-05-26

$Mind Medicine (MindMed) Inc.(MNMD)$Nice hello

2021-05-25

$Mind Medicine (MindMed) Inc.(MNMD)$Hahahahaha

2021-05-25

Nice

Sorry, the original content has been removed

2021-05-23

Txt txt t

2021-05-22

Thanks thanks

2021-05-20

Knut or no

2021-05-19

Thanks for information

Canada says reiterated to U.S. that it plans a digital services tax - minister

2021-05-19

Hehehehe be e skslskosss

Sorry, the original content has been removed

2021-05-19

$Mind Medicine (MindMed) Inc.(MNMD)$Sad day

2021-05-19

$Mind Medicine (MindMed) Inc.(MNMD)$Hello lost money

2021-05-17

$Mind Medicine (MindMed) Inc.(MNMD)$sad butlet’s ho

2021-05-16

Up since

2021-05-04

$Mind Medicine (MindMed) Inc.(MNMD)$Down bad

2021-05-04

Nice etf index

Sorry, the original content has been removed

2021-05-04

Testing like and comment

Sorry, the original content has been removed

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3582539332868122","uuid":"3582539332868122","gmtCreate":1619445308773,"gmtModify":1619574329056,"name":"ToMoonD","pinyin":"tomoond","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/f92d4ac39ec4bc607230f926b9344276","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":67,"tweetSize":35,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-1","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Debut Tiger","description":"Join the tiger community for 500 days","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.10","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":159656371,"gmtCreate":1624965340293,"gmtModify":1703848953189,"author":{"id":"3582539332868122","authorId":"3582539332868122","name":"ToMoonD","avatar":"https://static.tigerbbs.com/f92d4ac39ec4bc607230f926b9344276","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582539332868122","authorIdStr":"3582539332868122"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MNMD\">$Mind Medicine (MindMed) Inc.(MNMD)$</a>Hdshehejd","listText":"<a href=\"https://laohu8.com/S/MNMD\">$Mind Medicine (MindMed) Inc.(MNMD)$</a>Hdshehejd","text":"$Mind Medicine (MindMed) Inc.(MNMD)$Hdshehejd","images":[{"img":"https://static.tigerbbs.com/736086d0bcbf7e1764bfe6d178fabf46","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/159656371","isVote":1,"tweetType":1,"viewCount":277,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":127915644,"gmtCreate":1624813880788,"gmtModify":1703845481769,"author":{"id":"3582539332868122","authorId":"3582539332868122","name":"ToMoonD","avatar":"https://static.tigerbbs.com/f92d4ac39ec4bc607230f926b9344276","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582539332868122","authorIdStr":"3582539332868122"},"themes":[],"htmlText":"Shuhshsjddds","listText":"Shuhshsjddds","text":"Shuhshsjddds","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/127915644","repostId":"2146090006","repostType":4,"repost":{"id":"2146090006","pubTimestamp":1624755315,"share":"https://ttm.financial/m/news/2146090006?lang=&edition=fundamental","pubTime":"2021-06-27 08:55","market":"us","language":"en","title":"5 Buffett Stocks to Buy Hand Over Fist for the Second Half of 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=2146090006","media":"Motley Fool","summary":"These growth and value stocks are begging to be bought by investors.","content":"<p>When Warren Buffett buys or sells a stock, Wall Street and retail investors tend to pay very close attention. That's because the Oracle of Omaha's track record is virtually unsurpassed. Since taking the reins of <b>Berkshire Hathaway</b> (NYSE:BRK.A)(NYSE:BRK.B) in the mid-1960s, Buffett's company has averaged an annual return of 20%. This works out to an aggregate gain of greater than 2,800,000% for its Class A shares.</p>\n<p>Although Buffett isn't perfect, he and his investing team have a knack for identifying attractively valued businesses that have clear competitive advantages. As we prepare to move into the second half of 2021, the following five Buffett stocks stand out as those that should be bought hand over fist.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1077c8372814d2b8150e933b4c608005\" tg-width=\"700\" tg-height=\"466\"><span>Berkshire Hathaway CEO Warren Buffett. Image source: The Motley Fool.</span></p>\n<h2>Amazon</h2>\n<p>Even though Buffett's investing lieutenants, Todd Combs and Ted Weschler, are the architects behind Berkshire Hathaway's stake in <b>Amazon</b> (NASDAQ:AMZN), it's arguably the Buffett stock that should be bought most aggressively ahead of the second half of the year.</p>\n<p>As most folks probably know, Amazon is an e-commerce juggernaut. Based on an April report from eMarketer, the company effectively controls $0.40 of every $1 spent online in the United States. It's also pivoted its online retail popularity into signing up more than 200 million people to its Prime program worldwide. The fees Amazon collects from Prime help it to undercut its competition on price. And it certainly doesn't hurt that Prime members tend to spend many multiples more than non-Prime shoppers during the course of the year.</p>\n<p>But it's the company's cloud infrastructure service, Amazon Web Services (AWS), that has truly budded into a star. Since the operating margins associated with cloud infrastructure are considerably higher than what Amazon nets from retail and advertising, AWS' growth is leading to a surge in operating cash flow. If investors were to continue to pay the midpoint of Amazon's operating cash flow multiple over the past decade, it could hit $10,000 a share by 2025.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b18b49b2b35da2fc49e0a83b883d1c22\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Bristol Myers Squibb</h2>\n<p>Pharmaceutical stocks are money machines, and none looks to be more attractive on a valuation basis than <b>Bristol Myers Squibb</b> (NYSE:BMY).</p>\n<p>One reason to be excited about this drug developer is its organic growth potential. Eliquis, which was co-developed with <b>Pfizer</b>, has blossomed into the world's leading oral anticoagulant, with sales expected to surpass $10 billion in 2021. Meanwhile, dozens of additional clinical trials are underway for cancer immunotherapy Opdivo, which generated $7 billion in sales last year. This offers plenty of opportunity to expand Opdivo's label and pump up its pricing power.</p>\n<p>Another reason Bristol Myers Squibb is such an intriguing stock is its November 2019 acquisition of cancer and immunology company Celgene. Buying Celgene brought the blockbuster multiple-myeloma drug Revlimid into the fold. Revlimid has sustainably grown its annual sales by a double-digit percentage for more than a decade, with label expansion, longer duration of use, and pricing power all playing a role. This key treatment, which topped $12 billion in sales last year, is protected from a full onslaught of generic competition until early 2026. That means Bristol Myers will be rolling in the dough for another five years, at minimum.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1b152e369d7c967dcbc926192ee888c1\" tg-width=\"700\" tg-height=\"531\"><span>Image source: Getty Images.</span></p>\n<h2>Mastercard</h2>\n<p>Everyone seems to be looking for the smartest recovery play from the pandemic. Payment processor <b>Mastercard</b> (NYSE:MA) might well be the safest way to take advantage of a steady uptick in consumer and enterprise spending.</p>\n<p>Mastercard isn't a cheap stock by any means -- at 36 times Wall Street's forward-year earnings consensus -- but it benefits from a simple numbers game. While economic contractions and recessions are inevitable, these periods of turbulence tend to be short-lived. By comparison, economic expansions often last many years. Buying into Mastercard allows investors to take full advantage of these long periods of economic expansion and robust spending. Plus, it doesn't hurt that Mastercard has the second-highest share of credit-card network purchase volume in the U.S., the leading market for consumption.</p>\n<p>Investors can also sleep easy with the understanding that Mastercard strictly sticks to payment facilitation. Even though some of its peers also lend, and are therefore able to generate interest income and fees during bull markets, Mastercard has avoided becoming a lender. It's something you'll truly appreciate when a recession strikes. Whereas most financial stocks will be forced to set aside capital to cover credit or loan delinquencies, Mastercard won't have to. This is a big reason it bounces back from recessions quicker than most financial stocks.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e4e1a1fe028efa4c966b66ef2cd466f5\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Teva Pharmaceutical Industries</h2>\n<p>If you have an appetite for turnaround plays, brand-name and generic-drug developer <b>Teva Pharmaceutical Industries</b> (NYSE:TEVA) is the stock to buy hand over fist for the second half of 2021. Like Amazon, it's a stock that was added to Berkshire Hathaway's portfolio by either Combs or Weschler and not Buffett.</p>\n<p>While there's no denying that Teva has its fair share of hurdles to overcome, the company's turnaround-focused CEO, Kare Schultz, has been a blessing. Since taking the helm less than four years ago, Schultz has helped shave off more than $10 billion in net debt, and he's overseen the reduction of roughly $3 billion in annual operating expenses. There's more work to do to improve Teva's balance sheet, but the company is very clearly on much firmer ground than it was back in 2016-2017.</p>\n<p>Schultz also has the potential to play peacemaker for a number of outstanding lawsuits targeting Teva's role in the opioid crisis. If this litigation can be resolved with minimal cash outlay, Teva's valuation could soar. At just 4 times the company's projected earnings in 2021, Teva is about as cheap as a healthcare stock can get.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/44a30c4dfd6886a29e22d3c6558c3e56\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Bank of America</h2>\n<p>Lastly, bank stock <b>Bank of America</b> (NYSE:BAC) has the look of a company that can be confidently bought hand over fist for the second half of 2021.</p>\n<p>For much of the past decade, the Federal Reserve has kept interest rates at or near historic lows. That's meant less in the way of interest income for banks. But the latest update from the nation's central bank suggests that interest rates could begin creeping up in 2023, a year earlier than previously forecast. Bank of America is the most interest-sensitive money-center bank. According to its first-quarter investor presentation, BofA would generate $8.3 billion in net interest income on a 100-basis-point shift in the interest rate yield curve. Translation: Bank of America's profits should rocket higher beginning in 2023-2024.</p>\n<p>At the same time, BofA has done an outstanding job of controlling its costs and improving its operating efficiency. Investments in digitization have resulted in higher mobile app and digital banking use, which is allowing the company to consolidate some of its branches. Even with its shares at a 13-year high, Bank of America has plenty left in the tank.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Buffett Stocks to Buy Hand Over Fist for the Second Half of 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Buffett Stocks to Buy Hand Over Fist for the Second Half of 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-27 08:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/26/buffett-stocks-buy-hand-over-fist-second-half-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When Warren Buffett buys or sells a stock, Wall Street and retail investors tend to pay very close attention. That's because the Oracle of Omaha's track record is virtually unsurpassed. Since taking ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/26/buffett-stocks-buy-hand-over-fist-second-half-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BAC":"美国银行","AMZN":"亚马逊","BRK.A":"伯克希尔","TEVA":"梯瓦制药","BRK.B":"伯克希尔B","BMY":"施贵宝","MA":"万事达"},"source_url":"https://www.fool.com/investing/2021/06/26/buffett-stocks-buy-hand-over-fist-second-half-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146090006","content_text":"When Warren Buffett buys or sells a stock, Wall Street and retail investors tend to pay very close attention. That's because the Oracle of Omaha's track record is virtually unsurpassed. Since taking the reins of Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B) in the mid-1960s, Buffett's company has averaged an annual return of 20%. This works out to an aggregate gain of greater than 2,800,000% for its Class A shares.\nAlthough Buffett isn't perfect, he and his investing team have a knack for identifying attractively valued businesses that have clear competitive advantages. As we prepare to move into the second half of 2021, the following five Buffett stocks stand out as those that should be bought hand over fist.\nBerkshire Hathaway CEO Warren Buffett. Image source: The Motley Fool.\nAmazon\nEven though Buffett's investing lieutenants, Todd Combs and Ted Weschler, are the architects behind Berkshire Hathaway's stake in Amazon (NASDAQ:AMZN), it's arguably the Buffett stock that should be bought most aggressively ahead of the second half of the year.\nAs most folks probably know, Amazon is an e-commerce juggernaut. Based on an April report from eMarketer, the company effectively controls $0.40 of every $1 spent online in the United States. It's also pivoted its online retail popularity into signing up more than 200 million people to its Prime program worldwide. The fees Amazon collects from Prime help it to undercut its competition on price. And it certainly doesn't hurt that Prime members tend to spend many multiples more than non-Prime shoppers during the course of the year.\nBut it's the company's cloud infrastructure service, Amazon Web Services (AWS), that has truly budded into a star. Since the operating margins associated with cloud infrastructure are considerably higher than what Amazon nets from retail and advertising, AWS' growth is leading to a surge in operating cash flow. If investors were to continue to pay the midpoint of Amazon's operating cash flow multiple over the past decade, it could hit $10,000 a share by 2025.\nImage source: Getty Images.\nBristol Myers Squibb\nPharmaceutical stocks are money machines, and none looks to be more attractive on a valuation basis than Bristol Myers Squibb (NYSE:BMY).\nOne reason to be excited about this drug developer is its organic growth potential. Eliquis, which was co-developed with Pfizer, has blossomed into the world's leading oral anticoagulant, with sales expected to surpass $10 billion in 2021. Meanwhile, dozens of additional clinical trials are underway for cancer immunotherapy Opdivo, which generated $7 billion in sales last year. This offers plenty of opportunity to expand Opdivo's label and pump up its pricing power.\nAnother reason Bristol Myers Squibb is such an intriguing stock is its November 2019 acquisition of cancer and immunology company Celgene. Buying Celgene brought the blockbuster multiple-myeloma drug Revlimid into the fold. Revlimid has sustainably grown its annual sales by a double-digit percentage for more than a decade, with label expansion, longer duration of use, and pricing power all playing a role. This key treatment, which topped $12 billion in sales last year, is protected from a full onslaught of generic competition until early 2026. That means Bristol Myers will be rolling in the dough for another five years, at minimum.\nImage source: Getty Images.\nMastercard\nEveryone seems to be looking for the smartest recovery play from the pandemic. Payment processor Mastercard (NYSE:MA) might well be the safest way to take advantage of a steady uptick in consumer and enterprise spending.\nMastercard isn't a cheap stock by any means -- at 36 times Wall Street's forward-year earnings consensus -- but it benefits from a simple numbers game. While economic contractions and recessions are inevitable, these periods of turbulence tend to be short-lived. By comparison, economic expansions often last many years. Buying into Mastercard allows investors to take full advantage of these long periods of economic expansion and robust spending. Plus, it doesn't hurt that Mastercard has the second-highest share of credit-card network purchase volume in the U.S., the leading market for consumption.\nInvestors can also sleep easy with the understanding that Mastercard strictly sticks to payment facilitation. Even though some of its peers also lend, and are therefore able to generate interest income and fees during bull markets, Mastercard has avoided becoming a lender. It's something you'll truly appreciate when a recession strikes. Whereas most financial stocks will be forced to set aside capital to cover credit or loan delinquencies, Mastercard won't have to. This is a big reason it bounces back from recessions quicker than most financial stocks.\nImage source: Getty Images.\nTeva Pharmaceutical Industries\nIf you have an appetite for turnaround plays, brand-name and generic-drug developer Teva Pharmaceutical Industries (NYSE:TEVA) is the stock to buy hand over fist for the second half of 2021. Like Amazon, it's a stock that was added to Berkshire Hathaway's portfolio by either Combs or Weschler and not Buffett.\nWhile there's no denying that Teva has its fair share of hurdles to overcome, the company's turnaround-focused CEO, Kare Schultz, has been a blessing. Since taking the helm less than four years ago, Schultz has helped shave off more than $10 billion in net debt, and he's overseen the reduction of roughly $3 billion in annual operating expenses. There's more work to do to improve Teva's balance sheet, but the company is very clearly on much firmer ground than it was back in 2016-2017.\nSchultz also has the potential to play peacemaker for a number of outstanding lawsuits targeting Teva's role in the opioid crisis. If this litigation can be resolved with minimal cash outlay, Teva's valuation could soar. At just 4 times the company's projected earnings in 2021, Teva is about as cheap as a healthcare stock can get.\nImage source: Getty Images.\nBank of America\nLastly, bank stock Bank of America (NYSE:BAC) has the look of a company that can be confidently bought hand over fist for the second half of 2021.\nFor much of the past decade, the Federal Reserve has kept interest rates at or near historic lows. That's meant less in the way of interest income for banks. But the latest update from the nation's central bank suggests that interest rates could begin creeping up in 2023, a year earlier than previously forecast. Bank of America is the most interest-sensitive money-center bank. According to its first-quarter investor presentation, BofA would generate $8.3 billion in net interest income on a 100-basis-point shift in the interest rate yield curve. Translation: Bank of America's profits should rocket higher beginning in 2023-2024.\nAt the same time, BofA has done an outstanding job of controlling its costs and improving its operating efficiency. Investments in digitization have resulted in higher mobile app and digital banking use, which is allowing the company to consolidate some of its branches. Even with its shares at a 13-year high, Bank of America has plenty left in the tank.","news_type":1},"isVote":1,"tweetType":1,"viewCount":187,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":124317376,"gmtCreate":1624739167495,"gmtModify":1703844219362,"author":{"id":"3582539332868122","authorId":"3582539332868122","name":"ToMoonD","avatar":"https://static.tigerbbs.com/f92d4ac39ec4bc607230f926b9344276","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582539332868122","authorIdStr":"3582539332868122"},"themes":[],"htmlText":"Ok nice&nbsp;","listText":"Ok nice&nbsp;","text":"Ok nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/124317376","repostId":"2146500392","repostType":4,"repost":{"id":"2146500392","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1624658618,"share":"https://ttm.financial/m/news/2146500392?lang=&edition=fundamental","pubTime":"2021-06-26 06:03","market":"fut","language":"en","title":"Bitcoin falls 8.5% to $31,700","url":"https://stock-news.laohu8.com/highlight/detail?id=2146500392","media":"Reuters","summary":"June 25 (Reuters) - Bitcoin dipped 8.51% to $31,699.83 at 22:04 GMT on Friday, losing $2,937.27 from","content":"<p>June 25 (Reuters) - Bitcoin dipped 8.51% to $31,699.83 at 22:04 GMT on Friday, losing $2,937.27 from its previous close.</p>\n<p>Bitcoin, the world's biggest and best-known cryptocurrency, is up 14.3% from the year's low of $27,734 on Jan. 4.</p>\n<p>Ether, the coin linked to the ethereum blockchain network, dropped 7.37 % to $1,843.07 on Friday, losing $146.56 from its previous close.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bitcoin falls 8.5% to $31,700</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBitcoin falls 8.5% to $31,700\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-26 06:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>June 25 (Reuters) - Bitcoin dipped 8.51% to $31,699.83 at 22:04 GMT on Friday, losing $2,937.27 from its previous close.</p>\n<p>Bitcoin, the world's biggest and best-known cryptocurrency, is up 14.3% from the year's low of $27,734 on Jan. 4.</p>\n<p>Ether, the coin linked to the ethereum blockchain network, dropped 7.37 % to $1,843.07 on Friday, losing $146.56 from its previous close.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GBTC":"Grayscale Bitcoin Trust"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146500392","content_text":"June 25 (Reuters) - Bitcoin dipped 8.51% to $31,699.83 at 22:04 GMT on Friday, losing $2,937.27 from its previous close.\nBitcoin, the world's biggest and best-known cryptocurrency, is up 14.3% from the year's low of $27,734 on Jan. 4.\nEther, the coin linked to the ethereum blockchain network, dropped 7.37 % to $1,843.07 on Friday, losing $146.56 from its previous close.","news_type":1},"isVote":1,"tweetType":1,"viewCount":106,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":129055340,"gmtCreate":1624347013980,"gmtModify":1703834071003,"author":{"id":"3582539332868122","authorId":"3582539332868122","name":"ToMoonD","avatar":"https://static.tigerbbs.com/f92d4ac39ec4bc607230f926b9344276","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582539332868122","authorIdStr":"3582539332868122"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MNMD\">$Mind Medicine (MindMed) Inc.(MNMD)$</a>Nooo let’s ho","listText":"<a href=\"https://laohu8.com/S/MNMD\">$Mind Medicine (MindMed) Inc.(MNMD)$</a>Nooo let’s ho","text":"$Mind Medicine (MindMed) Inc.(MNMD)$Nooo let’s ho","images":[{"img":"https://static.tigerbbs.com/fb9c8ac3190a0450cce2ae42d63c8b30","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/129055340","isVote":1,"tweetType":1,"viewCount":286,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":136241532,"gmtCreate":1622023596126,"gmtModify":1704366266040,"author":{"id":"3582539332868122","authorId":"3582539332868122","name":"ToMoonD","avatar":"https://static.tigerbbs.com/f92d4ac39ec4bc607230f926b9344276","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582539332868122","authorIdStr":"3582539332868122"},"themes":[],"htmlText":"Hdkeold","listText":"Hdkeold","text":"Hdkeold","images":[{"img":"https://static.tigerbbs.com/35e4d3488831a5a278323843446e2244","width":"750","height":"2162"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/136241532","isVote":1,"tweetType":1,"viewCount":175,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":136241816,"gmtCreate":1622023570035,"gmtModify":1704366265877,"author":{"id":"3582539332868122","authorId":"3582539332868122","name":"ToMoonD","avatar":"https://static.tigerbbs.com/f92d4ac39ec4bc607230f926b9344276","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582539332868122","authorIdStr":"3582539332868122"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MNMD\">$Mind Medicine (MindMed) Inc.(MNMD)$</a>Nice hello","listText":"<a href=\"https://laohu8.com/S/MNMD\">$Mind Medicine (MindMed) Inc.(MNMD)$</a>Nice hello","text":"$Mind Medicine (MindMed) Inc.(MNMD)$Nice hello","images":[{"img":"https://static.tigerbbs.com/5b375c29ff52da1b3f7167a2ac49dc26","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/136241816","isVote":1,"tweetType":1,"viewCount":259,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":131440319,"gmtCreate":1621883692531,"gmtModify":1704363782069,"author":{"id":"3582539332868122","authorId":"3582539332868122","name":"ToMoonD","avatar":"https://static.tigerbbs.com/f92d4ac39ec4bc607230f926b9344276","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582539332868122","authorIdStr":"3582539332868122"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MNMD\">$Mind Medicine (MindMed) Inc.(MNMD)$</a>Hahahahaha","listText":"<a href=\"https://laohu8.com/S/MNMD\">$Mind Medicine (MindMed) Inc.(MNMD)$</a>Hahahahaha","text":"$Mind Medicine (MindMed) Inc.(MNMD)$Hahahahaha","images":[{"img":"https://static.tigerbbs.com/a72d5416da78f84c5ac4e18f474e6c4d","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/131440319","isVote":1,"tweetType":1,"viewCount":173,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":131440934,"gmtCreate":1621883640528,"gmtModify":1704363781422,"author":{"id":"3582539332868122","authorId":"3582539332868122","name":"ToMoonD","avatar":"https://static.tigerbbs.com/f92d4ac39ec4bc607230f926b9344276","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582539332868122","authorIdStr":"3582539332868122"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/131440934","repostId":"2137155528","repostType":4,"isVote":1,"tweetType":1,"viewCount":373,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":133420535,"gmtCreate":1621785110627,"gmtModify":1704362395934,"author":{"id":"3582539332868122","authorId":"3582539332868122","name":"ToMoonD","avatar":"https://static.tigerbbs.com/f92d4ac39ec4bc607230f926b9344276","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582539332868122","authorIdStr":"3582539332868122"},"themes":[],"htmlText":"Txt txt t&nbsp;","listText":"Txt txt t&nbsp;","text":"Txt txt t","images":[{"img":"https://static.tigerbbs.com/27d01dd0a09a2717b299a7ff8df6c24e","width":"750","height":"2053"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/133420535","isVote":1,"tweetType":1,"viewCount":262,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":139667452,"gmtCreate":1621615773176,"gmtModify":1704360642221,"author":{"id":"3582539332868122","authorId":"3582539332868122","name":"ToMoonD","avatar":"https://static.tigerbbs.com/f92d4ac39ec4bc607230f926b9344276","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582539332868122","authorIdStr":"3582539332868122"},"themes":[],"htmlText":"Thanks thanks&nbsp;","listText":"Thanks thanks&nbsp;","text":"Thanks thanks","images":[{"img":"https://static.tigerbbs.com/2700dbff5c020083f6a7b26f90c36ded","width":"750","height":"2153"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/139667452","isVote":1,"tweetType":1,"viewCount":178,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":197705807,"gmtCreate":1621483629709,"gmtModify":1704358360979,"author":{"id":"3582539332868122","authorId":"3582539332868122","name":"ToMoonD","avatar":"https://static.tigerbbs.com/f92d4ac39ec4bc607230f926b9344276","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582539332868122","authorIdStr":"3582539332868122"},"themes":[],"htmlText":"Knut or no&nbsp;","listText":"Knut or no&nbsp;","text":"Knut or no","images":[{"img":"https://static.tigerbbs.com/4e8a9594e0a053e5359abf457e8a6b1b","width":"750","height":"1870"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/197705807","isVote":1,"tweetType":1,"viewCount":41,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":197006145,"gmtCreate":1621407103787,"gmtModify":1704357120380,"author":{"id":"3582539332868122","authorId":"3582539332868122","name":"ToMoonD","avatar":"https://static.tigerbbs.com/f92d4ac39ec4bc607230f926b9344276","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582539332868122","authorIdStr":"3582539332868122"},"themes":[],"htmlText":"Thanks for information&nbsp;","listText":"Thanks for information&nbsp;","text":"Thanks for information","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/197006145","repostId":"2136701992","repostType":4,"repost":{"id":"2136701992","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1621385740,"share":"https://ttm.financial/m/news/2136701992?lang=&edition=fundamental","pubTime":"2021-05-19 08:55","market":"us","language":"en","title":"Canada says reiterated to U.S. that it plans a digital services tax - minister","url":"https://stock-news.laohu8.com/highlight/detail?id=2136701992","media":"Reuters","summary":"OTTAWA, May 18 (Reuters) - Canada reiterated to the United States that it plans to go ahead with a d","content":"<p>OTTAWA, May 18 (Reuters) - Canada reiterated to the United States that it plans to go ahead with a digital services tax if need be, a move that would hit giants like Alphabet Inc's</p><p>Google and <a href=\"https://laohu8.com/S/FB\">Facebook</a> Inc, Trade Minister Mary Ng said on Tuesday.</p><p>Ng told reporters she made the remarks in bilateral talks with U.S. Trade Representative Katherine Tai, who on Monday had expressed concern about the plan. Canada said last November it intended to impose a tax on corporations providing digital services from 2022.</p><p>Ottawa said the levy would stay in place until major nations come up with a coordinated approach on taxing digital giants.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Canada says reiterated to U.S. that it plans a digital services tax - minister</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCanada says reiterated to U.S. that it plans a digital services tax - minister\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-05-19 08:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>OTTAWA, May 18 (Reuters) - Canada reiterated to the United States that it plans to go ahead with a digital services tax if need be, a move that would hit giants like Alphabet Inc's</p><p>Google and <a href=\"https://laohu8.com/S/FB\">Facebook</a> Inc, Trade Minister Mary Ng said on Tuesday.</p><p>Ng told reporters she made the remarks in bilateral talks with U.S. Trade Representative Katherine Tai, who on Monday had expressed concern about the plan. Canada said last November it intended to impose a tax on corporations providing digital services from 2022.</p><p>Ottawa said the levy would stay in place until major nations come up with a coordinated approach on taxing digital giants.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GOOG":"谷歌","GOOGL":"谷歌A"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2136701992","content_text":"OTTAWA, May 18 (Reuters) - Canada reiterated to the United States that it plans to go ahead with a digital services tax if need be, a move that would hit giants like Alphabet Inc'sGoogle and Facebook Inc, Trade Minister Mary Ng said on Tuesday.Ng told reporters she made the remarks in bilateral talks with U.S. Trade Representative Katherine Tai, who on Monday had expressed concern about the plan. Canada said last November it intended to impose a tax on corporations providing digital services from 2022.Ottawa said the levy would stay in place until major nations come up with a coordinated approach on taxing digital giants.","news_type":1},"isVote":1,"tweetType":1,"viewCount":72,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":197006962,"gmtCreate":1621407087656,"gmtModify":1704357119852,"author":{"id":"3582539332868122","authorId":"3582539332868122","name":"ToMoonD","avatar":"https://static.tigerbbs.com/f92d4ac39ec4bc607230f926b9344276","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582539332868122","authorIdStr":"3582539332868122"},"themes":[],"htmlText":"Hehehehe be e skslskosss","listText":"Hehehehe be e skslskosss","text":"Hehehehe be e skslskosss","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/197006962","repostId":"2136419997","repostType":4,"isVote":1,"tweetType":1,"viewCount":221,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":197001601,"gmtCreate":1621406897003,"gmtModify":1704357118878,"author":{"id":"3582539332868122","authorId":"3582539332868122","name":"ToMoonD","avatar":"https://static.tigerbbs.com/f92d4ac39ec4bc607230f926b9344276","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582539332868122","authorIdStr":"3582539332868122"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MNMD\">$Mind Medicine (MindMed) Inc.(MNMD)$</a>Sad day","listText":"<a href=\"https://laohu8.com/S/MNMD\">$Mind Medicine (MindMed) Inc.(MNMD)$</a>Sad day","text":"$Mind Medicine (MindMed) Inc.(MNMD)$Sad day","images":[{"img":"https://static.tigerbbs.com/0adeb58019d90281e26a09c7a759cdcb","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/197001601","isVote":1,"tweetType":1,"viewCount":198,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":194846303,"gmtCreate":1621360151902,"gmtModify":1704356410423,"author":{"id":"3582539332868122","authorId":"3582539332868122","name":"ToMoonD","avatar":"https://static.tigerbbs.com/f92d4ac39ec4bc607230f926b9344276","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582539332868122","authorIdStr":"3582539332868122"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MNMD\">$Mind Medicine (MindMed) Inc.(MNMD)$</a>Hello lost money","listText":"<a href=\"https://laohu8.com/S/MNMD\">$Mind Medicine (MindMed) Inc.(MNMD)$</a>Hello lost money","text":"$Mind Medicine (MindMed) Inc.(MNMD)$Hello lost money","images":[{"img":"https://static.tigerbbs.com/00f79dc9942b1e0ff86c87bff4fe0a21","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/194846303","isVote":1,"tweetType":1,"viewCount":222,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":192877066,"gmtCreate":1621199454555,"gmtModify":1704353717289,"author":{"id":"3582539332868122","authorId":"3582539332868122","name":"ToMoonD","avatar":"https://static.tigerbbs.com/f92d4ac39ec4bc607230f926b9344276","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582539332868122","authorIdStr":"3582539332868122"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MNMD\">$Mind Medicine (MindMed) Inc.(MNMD)$</a>sad butlet’s ho","listText":"<a href=\"https://laohu8.com/S/MNMD\">$Mind Medicine (MindMed) Inc.(MNMD)$</a>sad butlet’s ho","text":"$Mind Medicine (MindMed) Inc.(MNMD)$sad butlet’s ho","images":[{"img":"https://static.tigerbbs.com/b4d694095f0f203aacb0862520ae1d33","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/192877066","isVote":1,"tweetType":1,"viewCount":146,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":192161349,"gmtCreate":1621164024481,"gmtModify":1704353522243,"author":{"id":"3582539332868122","authorId":"3582539332868122","name":"ToMoonD","avatar":"https://static.tigerbbs.com/f92d4ac39ec4bc607230f926b9344276","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582539332868122","authorIdStr":"3582539332868122"},"themes":[],"htmlText":"Up since&nbsp;","listText":"Up since&nbsp;","text":"Up since","images":[{"img":"https://static.tigerbbs.com/2520fb3b4b4486a0e42775ec59a34fa1","width":"750","height":"2053"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/192161349","isVote":1,"tweetType":1,"viewCount":135,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":106526581,"gmtCreate":1620135568443,"gmtModify":1704339118528,"author":{"id":"3582539332868122","authorId":"3582539332868122","name":"ToMoonD","avatar":"https://static.tigerbbs.com/f92d4ac39ec4bc607230f926b9344276","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582539332868122","authorIdStr":"3582539332868122"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MNMD\">$Mind Medicine (MindMed) Inc.(MNMD)$</a>Down bad","listText":"<a href=\"https://laohu8.com/S/MNMD\">$Mind Medicine (MindMed) Inc.(MNMD)$</a>Down bad","text":"$Mind Medicine (MindMed) Inc.(MNMD)$Down bad","images":[{"img":"https://static.tigerbbs.com/bfd355bb2a75d7e5f1fcf6a801018da9","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/106526581","isVote":1,"tweetType":1,"viewCount":256,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":106526036,"gmtCreate":1620135544725,"gmtModify":1704339117883,"author":{"id":"3582539332868122","authorId":"3582539332868122","name":"ToMoonD","avatar":"https://static.tigerbbs.com/f92d4ac39ec4bc607230f926b9344276","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582539332868122","authorIdStr":"3582539332868122"},"themes":[],"htmlText":"Nice etf index","listText":"Nice etf index","text":"Nice etf index","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/106526036","repostId":"1119128956","repostType":4,"isVote":1,"tweetType":1,"viewCount":179,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":106528564,"gmtCreate":1620135532558,"gmtModify":1704339117561,"author":{"id":"3582539332868122","authorId":"3582539332868122","name":"ToMoonD","avatar":"https://static.tigerbbs.com/f92d4ac39ec4bc607230f926b9344276","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582539332868122","authorIdStr":"3582539332868122"},"themes":[],"htmlText":"Testing like and comment","listText":"Testing like and comment","text":"Testing like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/106528564","repostId":"1142616846","repostType":4,"isVote":1,"tweetType":1,"viewCount":120,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":108097262,"gmtCreate":1619957303256,"gmtModify":1704336761805,"author":{"id":"3582539332868122","authorId":"3582539332868122","name":"ToMoonD","avatar":"https://static.tigerbbs.com/f92d4ac39ec4bc607230f926b9344276","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582539332868122","idStr":"3582539332868122"},"themes":[],"htmlText":"Hello pls like and comment","listText":"Hello pls like and comment","text":"Hello pls like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/108097262","repostId":"1138497242","repostType":4,"repost":{"id":"1138497242","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1619794882,"share":"https://ttm.financial/m/news/1138497242?lang=&edition=fundamental","pubTime":"2021-04-30 23:01","market":"us","language":"en","title":"Twitter may struggle to replicate bumper 2020 growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1138497242","media":"Reuters","summary":"Twitter Inc will struggle to replicate a bumper 2020 dominated by the U.S. political battles, civil ","content":"<p>Twitter Inc will struggle to replicate a bumper 2020 dominated by the U.S. political battles, civil unrest and the COVID-19 crisis as people venture out following vaccine rollouts, Wall Street analysts said on Friday.</p><p>The lifting of restrictions as people get vaccinated has largely seen benefiting other digital ad firms such as Facebook Inc and Alphabet Inc’s Google whose stocks soared after reporting blockbuster results this week.</p><p>Not so with Twitter. Shares sank more than 12% on Friday after the social media company reported first-quarter revenue and user numbers mostly in line with analyst estimates and warned the current quarter could be its worse as it eyed a weaker 2021.</p><p>“The company’s weak future guidance suggests that repeating this performance will be extremely difficult,” said Haris Anwar, senior analyst at Investing.com, adding that more people will look to engage in offline activities as the vaccine rollouts pick up.</p><p>Although other tech companies have warned of a drop in users this year, they are still upbeat on ad spending as marketers try to target consumers eager to spend and travel after being locked indoors for over a year.</p><p>“Twitter doesn’t seem well positioned to actually capture the most dynamic part of the digital advertising economy as they lack both sufficient scale of users and the first party data signals that attract performance based marketers,” said Michael Nathanson, senior research analyst at MoffetNathanson LLC.</p><p>A vow to focus on new products and features by Twitter did little to allay investor concerns on Friday.</p><p>However, some analysts found the company’s current-quarter revenue forecast conservative as they expect newer app features and return of live events to boost user engagement and monetization in coming months.</p><p>At least eight brokerages cut their price targets on Twitter after the company forecast tepid revenue growth for the second quarter.</p><p>Of the 40 analysts covering the stock, 29 have a “hold” or lower rating and the rest have a “buy” or higher rating. The current median price target on the stock is $70, as per Refinitiv data. </p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Twitter may struggle to replicate bumper 2020 growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTwitter may struggle to replicate bumper 2020 growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-04-30 23:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Twitter Inc will struggle to replicate a bumper 2020 dominated by the U.S. political battles, civil unrest and the COVID-19 crisis as people venture out following vaccine rollouts, Wall Street analysts said on Friday.</p><p>The lifting of restrictions as people get vaccinated has largely seen benefiting other digital ad firms such as Facebook Inc and Alphabet Inc’s Google whose stocks soared after reporting blockbuster results this week.</p><p>Not so with Twitter. Shares sank more than 12% on Friday after the social media company reported first-quarter revenue and user numbers mostly in line with analyst estimates and warned the current quarter could be its worse as it eyed a weaker 2021.</p><p>“The company’s weak future guidance suggests that repeating this performance will be extremely difficult,” said Haris Anwar, senior analyst at Investing.com, adding that more people will look to engage in offline activities as the vaccine rollouts pick up.</p><p>Although other tech companies have warned of a drop in users this year, they are still upbeat on ad spending as marketers try to target consumers eager to spend and travel after being locked indoors for over a year.</p><p>“Twitter doesn’t seem well positioned to actually capture the most dynamic part of the digital advertising economy as they lack both sufficient scale of users and the first party data signals that attract performance based marketers,” said Michael Nathanson, senior research analyst at MoffetNathanson LLC.</p><p>A vow to focus on new products and features by Twitter did little to allay investor concerns on Friday.</p><p>However, some analysts found the company’s current-quarter revenue forecast conservative as they expect newer app features and return of live events to boost user engagement and monetization in coming months.</p><p>At least eight brokerages cut their price targets on Twitter after the company forecast tepid revenue growth for the second quarter.</p><p>Of the 40 analysts covering the stock, 29 have a “hold” or lower rating and the rest have a “buy” or higher rating. The current median price target on the stock is $70, as per Refinitiv data. </p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TWTR":"Twitter"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138497242","content_text":"Twitter Inc will struggle to replicate a bumper 2020 dominated by the U.S. political battles, civil unrest and the COVID-19 crisis as people venture out following vaccine rollouts, Wall Street analysts said on Friday.The lifting of restrictions as people get vaccinated has largely seen benefiting other digital ad firms such as Facebook Inc and Alphabet Inc’s Google whose stocks soared after reporting blockbuster results this week.Not so with Twitter. Shares sank more than 12% on Friday after the social media company reported first-quarter revenue and user numbers mostly in line with analyst estimates and warned the current quarter could be its worse as it eyed a weaker 2021.“The company’s weak future guidance suggests that repeating this performance will be extremely difficult,” said Haris Anwar, senior analyst at Investing.com, adding that more people will look to engage in offline activities as the vaccine rollouts pick up.Although other tech companies have warned of a drop in users this year, they are still upbeat on ad spending as marketers try to target consumers eager to spend and travel after being locked indoors for over a year.“Twitter doesn’t seem well positioned to actually capture the most dynamic part of the digital advertising economy as they lack both sufficient scale of users and the first party data signals that attract performance based marketers,” said Michael Nathanson, senior research analyst at MoffetNathanson LLC.A vow to focus on new products and features by Twitter did little to allay investor concerns on Friday.However, some analysts found the company’s current-quarter revenue forecast conservative as they expect newer app features and return of live events to boost user engagement and monetization in coming months.At least eight brokerages cut their price targets on Twitter after the company forecast tepid revenue growth for the second quarter.Of the 40 analysts covering the stock, 29 have a “hold” or lower rating and the rest have a “buy” or higher rating. The current median price target on the stock is $70, as per Refinitiv data.","news_type":1},"isVote":1,"tweetType":1,"viewCount":139,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":108094255,"gmtCreate":1619957170277,"gmtModify":1704336760971,"author":{"id":"3582539332868122","authorId":"3582539332868122","name":"ToMoonD","avatar":"https://static.tigerbbs.com/f92d4ac39ec4bc607230f926b9344276","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582539332868122","idStr":"3582539332868122"},"themes":[],"htmlText":"Nice comment","listText":"Nice comment","text":"Nice comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/108094255","repostId":"1165708828","repostType":4,"repost":{"id":"1165708828","pubTimestamp":1619792862,"share":"https://ttm.financial/m/news/1165708828?lang=&edition=fundamental","pubTime":"2021-04-30 22:27","market":"us","language":"en","title":"3 Turnaround Stocks With 91% to 104% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1165708828","media":"Motley Fool","summary":"For more than a year, patient investors have been handsomely rewarded. All three of the market's maj","content":"<p>For more than a year, patient investors have been handsomely rewarded. All three of the market's major indexes have gained between 83% and 106% since hitting the bear-market bottom set on March 23, 2020.</p>\n<p>Yet, not all stocks have participated in the rally. Over the trailing year (through April 27, 2021), around 110 stocks with at least a $300 million market cap have declined by 20% (or more). Given the aforementioned big gains in the<b>S&amp;P 500</b>,<b>Dow Jones Industrial Average</b>, and<b>Nasdaq Composite</b>, this represents a huge underperformance.</p>\n<p>But according to analysts on Wall Street, some of these underperformers have a good chance to bounce back in a big way over the coming year. Based on consensus one-year price targets, the following three turnaround stocks offer upside ranging from 91% to as much as 104%.</p>\n<p>Sarepta Therapeutics: Implied upside of 91%</p>\n<p>Many of the worst-performing equities over the past year arebiotech stocks. With investors rolling the dice on future clinical outcomes, trial data announcements can yield wild price swings for drug developers. Shareholders of specialized drug developer<b>Sarepta Therapeutics</b>(NASDAQ:SRPT)learned this in January when shares of the company were halved in a day. But if Wall Street's one-year price target is correct, Sarepta could recoup most of its losses by gaining 91% from its April 27 close.</p>\n<p>Sarepta's bread and butter is its research in treating Duchenne Muscular Dystrophy (DMD). DMD is an incurable disease diagnosed in children that leads to the destruction of muscle and causes premature death. To date, the company has had the U.S. Food and Drug Administration (FDA) approve three of its gene-specific DMD treatments, which are designed to increase the production of dystrophin.</p>\n<p>However, themake-or-break treatmentin the company's pipeline is SRP-9001. This is an experimental treatment that utilizes an adeno-associated virus to deliver a gene to muscle tissue that \"programs\" for micro-dystrophin production.&nbsp; In other words, SRP-9001 would allow the company to treat a much larger percentage of DMD patients.</p>\n<p>The Part 1 data release of Study 102 evaluating SRP-9001 in DMD patients aged 4 to 7 is why the stock was halved in January. Although treated participants showed an increase in their North Star Ambulatory Assessment (NSAA) total score,it wasn't statistically significant. Sarepta, however, blamed this disappointment on fitness differences in its patients during the study and expects a much different outcome in the latter half of this study. Part 2 of Study 102 is, therefore, Sarepta's make-or-break DMD moment.</p>\n<p>Intercept Pharmaceuticals: Implied upside of 97%</p>\n<p>If you wanteven more upside potential, Wall Street would steer you toward small-cap<b>Intercept Pharmaceuticals</b>(NASDAQ:ICPT). Among the 4,000-plus securities with at least a $300 million market cap, it holds the distinction of being the absolute worst performer over the trailing year (down 75%). The only solace is that Wall Street's consensus price target would see Intercept gain 97% over the coming year.</p>\n<p>Similar to Sarepta, Intercept's future predominantly lies with one indication: nonalcoholic steatohepatitis, or NASH. NASH is a liver disease that affects between 2% and 5% of the U.S. adult population and has no FDA-approved cure. It can lead to fibrosis, liver cancer, and even death. It's been estimated that NASH represents a $35 billion treatment opportunity.</p>\n<p>Intercept is at the forefront of that opportunity, but it's not been without its hiccups. Experimental treatment obeticholic acid (OCA)met one of its two co-primary endpointsin the phase 3 Regenerate study -- a statistically significant reduction in liver fibrosis without a worsening in NASH. Only one met endpoint was needed to declare the trial a success.</p>\n<p>On the other hand, the highest dose (also the most effective) led to considerably higher instances of pruritus (itching) and trial discontinuation, relative to the placebo. Perhaps unsurprisingly, Interceptreceived a Complete Response Letterfrom the FDA following its new drug application to supply additional safety data.</p>\n<p>If OCA were to be approved, even for a small subset of the sickest patients, it would represent a greater than $1 billion sales opportunity.</p>\n<p>It's also worth noting that OCA is already approved under the brand name Ocaliva as a treatment for primary biliary cholangitis (PBC). With Ocaliva's PBC sales expected to hit at least $325 million in 2021 (nearly half the company's market cap), investors look to begetting a shot at NASH success nearly for free.</p>\n<p>Inovio Pharmaceuticals: Implied upside of 104%</p>\n<p>Yet another biotech stock withbig-time upside potential, according to Wall Street, is<b>Inovio Pharmaceuticals</b>(NASDAQ:INO). Shares of the company have been clobbered recently, but are expected to rally by 104% to nearly $15 based on the consensus 12-month price target of analysts.</p>\n<p>For much of the past year, the promise and peril of Inovio have rested with its development of a coronavirus disease 2019 (COVID-19) vaccine. The company's candidate, INO-4800, achieved immunological responses in 38 of 38 patients in phase 1 studies and looked to be on track to be among the roughly six or so early contenders to bring a COVID-19 vaccine to market in the United States.</p>\n<p>Unfortunately, Inovio's phase 2 and 3 studies hit a snag. The FDA placed a partial clinical hold on both phases and requested additional information concerning INO-4800 and the company's Cellectra delivery device. Cellectra uses electrical impulses to open pores in cells to allow plasmids to enter. Though the partial hold on the phase 2 study was lifted, the company has yet to run an all-important phase 3 study and may choose to do so outside the United States. To top things off, the U.S. Department of Defense notified Inovio that it wouldno longer be providing funding for its phase 3 study.</p>\n<p>There are two very big problems here. First, Inovio is running out of time to become a major player in treating COVID-19. The U.S. vaccination campaign will likely be complete sometime in July, and major players like<b>Johnson &amp; Johnson</b>&nbsp;can produce up to 3 billion doses for the global market this year. As a reminder, J&amp;J's vaccine is a single-dose treatment.</p>\n<p>The other potential red flag isInovio's track record. The company may have an intriguing delivery device in Cellectra, as well as nearly a dozen unique compounds in clinical trials, but it's yet to have the FDA approve any of its experimental treatments in four decades.</p>\n<p>With a number of its studies partnered, it's always possible Inovio could turn itself around. But given its track record, it may be best off avoided.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Turnaround Stocks With 91% to 104% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Turnaround Stocks With 91% to 104% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-30 22:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/30/3-turnaround-stocks-91-to-104-upside-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For more than a year, patient investors have been handsomely rewarded. All three of the market's major indexes have gained between 83% and 106% since hitting the bear-market bottom set on March 23, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/30/3-turnaround-stocks-91-to-104-upside-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/04/30/3-turnaround-stocks-91-to-104-upside-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165708828","content_text":"For more than a year, patient investors have been handsomely rewarded. All three of the market's major indexes have gained between 83% and 106% since hitting the bear-market bottom set on March 23, 2020.\nYet, not all stocks have participated in the rally. Over the trailing year (through April 27, 2021), around 110 stocks with at least a $300 million market cap have declined by 20% (or more). Given the aforementioned big gains in theS&P 500,Dow Jones Industrial Average, andNasdaq Composite, this represents a huge underperformance.\nBut according to analysts on Wall Street, some of these underperformers have a good chance to bounce back in a big way over the coming year. Based on consensus one-year price targets, the following three turnaround stocks offer upside ranging from 91% to as much as 104%.\nSarepta Therapeutics: Implied upside of 91%\nMany of the worst-performing equities over the past year arebiotech stocks. With investors rolling the dice on future clinical outcomes, trial data announcements can yield wild price swings for drug developers. Shareholders of specialized drug developerSarepta Therapeutics(NASDAQ:SRPT)learned this in January when shares of the company were halved in a day. But if Wall Street's one-year price target is correct, Sarepta could recoup most of its losses by gaining 91% from its April 27 close.\nSarepta's bread and butter is its research in treating Duchenne Muscular Dystrophy (DMD). DMD is an incurable disease diagnosed in children that leads to the destruction of muscle and causes premature death. To date, the company has had the U.S. Food and Drug Administration (FDA) approve three of its gene-specific DMD treatments, which are designed to increase the production of dystrophin.\nHowever, themake-or-break treatmentin the company's pipeline is SRP-9001. This is an experimental treatment that utilizes an adeno-associated virus to deliver a gene to muscle tissue that \"programs\" for micro-dystrophin production.  In other words, SRP-9001 would allow the company to treat a much larger percentage of DMD patients.\nThe Part 1 data release of Study 102 evaluating SRP-9001 in DMD patients aged 4 to 7 is why the stock was halved in January. Although treated participants showed an increase in their North Star Ambulatory Assessment (NSAA) total score,it wasn't statistically significant. Sarepta, however, blamed this disappointment on fitness differences in its patients during the study and expects a much different outcome in the latter half of this study. Part 2 of Study 102 is, therefore, Sarepta's make-or-break DMD moment.\nIntercept Pharmaceuticals: Implied upside of 97%\nIf you wanteven more upside potential, Wall Street would steer you toward small-capIntercept Pharmaceuticals(NASDAQ:ICPT). Among the 4,000-plus securities with at least a $300 million market cap, it holds the distinction of being the absolute worst performer over the trailing year (down 75%). The only solace is that Wall Street's consensus price target would see Intercept gain 97% over the coming year.\nSimilar to Sarepta, Intercept's future predominantly lies with one indication: nonalcoholic steatohepatitis, or NASH. NASH is a liver disease that affects between 2% and 5% of the U.S. adult population and has no FDA-approved cure. It can lead to fibrosis, liver cancer, and even death. It's been estimated that NASH represents a $35 billion treatment opportunity.\nIntercept is at the forefront of that opportunity, but it's not been without its hiccups. Experimental treatment obeticholic acid (OCA)met one of its two co-primary endpointsin the phase 3 Regenerate study -- a statistically significant reduction in liver fibrosis without a worsening in NASH. Only one met endpoint was needed to declare the trial a success.\nOn the other hand, the highest dose (also the most effective) led to considerably higher instances of pruritus (itching) and trial discontinuation, relative to the placebo. Perhaps unsurprisingly, Interceptreceived a Complete Response Letterfrom the FDA following its new drug application to supply additional safety data.\nIf OCA were to be approved, even for a small subset of the sickest patients, it would represent a greater than $1 billion sales opportunity.\nIt's also worth noting that OCA is already approved under the brand name Ocaliva as a treatment for primary biliary cholangitis (PBC). With Ocaliva's PBC sales expected to hit at least $325 million in 2021 (nearly half the company's market cap), investors look to begetting a shot at NASH success nearly for free.\nInovio Pharmaceuticals: Implied upside of 104%\nYet another biotech stock withbig-time upside potential, according to Wall Street, isInovio Pharmaceuticals(NASDAQ:INO). Shares of the company have been clobbered recently, but are expected to rally by 104% to nearly $15 based on the consensus 12-month price target of analysts.\nFor much of the past year, the promise and peril of Inovio have rested with its development of a coronavirus disease 2019 (COVID-19) vaccine. The company's candidate, INO-4800, achieved immunological responses in 38 of 38 patients in phase 1 studies and looked to be on track to be among the roughly six or so early contenders to bring a COVID-19 vaccine to market in the United States.\nUnfortunately, Inovio's phase 2 and 3 studies hit a snag. The FDA placed a partial clinical hold on both phases and requested additional information concerning INO-4800 and the company's Cellectra delivery device. Cellectra uses electrical impulses to open pores in cells to allow plasmids to enter. Though the partial hold on the phase 2 study was lifted, the company has yet to run an all-important phase 3 study and may choose to do so outside the United States. To top things off, the U.S. Department of Defense notified Inovio that it wouldno longer be providing funding for its phase 3 study.\nThere are two very big problems here. First, Inovio is running out of time to become a major player in treating COVID-19. The U.S. vaccination campaign will likely be complete sometime in July, and major players likeJohnson & Johnson can produce up to 3 billion doses for the global market this year. As a reminder, J&J's vaccine is a single-dose treatment.\nThe other potential red flag isInovio's track record. The company may have an intriguing delivery device in Cellectra, as well as nearly a dozen unique compounds in clinical trials, but it's yet to have the FDA approve any of its experimental treatments in four decades.\nWith a number of its studies partnered, it's always possible Inovio could turn itself around. But given its track record, it may be best off avoided.","news_type":1},"isVote":1,"tweetType":1,"viewCount":115,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":131440934,"gmtCreate":1621883640528,"gmtModify":1704363781422,"author":{"id":"3582539332868122","authorId":"3582539332868122","name":"ToMoonD","avatar":"https://static.tigerbbs.com/f92d4ac39ec4bc607230f926b9344276","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582539332868122","idStr":"3582539332868122"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/131440934","repostId":"2137155528","repostType":4,"repost":{"id":"2137155528","weMediaInfo":{"introduction":"The leading daily newsletter for the latest financial and business news. 33Yrs Helping Stock Investors with Investing Insights, Tools, News & More.","home_visible":0,"media_name":"Investors","id":"1085713068","head_image":"https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c"},"pubTimestamp":1621868886,"share":"https://ttm.financial/m/news/2137155528?lang=&edition=fundamental","pubTime":"2021-05-24 23:08","market":"us","language":"en","title":"Trading A Broken Wing Butterfly In Netflix Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2137155528","media":"Investors","summary":"For those with a slightly bearish outlook, a broken wing butterfly could be a nice way to trade Netflix stock.","content":"<p><b>Netflix</b> stock is struggling to break above 500 and is currently below the 50- and 200-day moving averages.</p><p>Today, I want to look at a strategy with very low risk on the upside and a healthy profit zone on the downside.</p><p>The strategy is called a broken wing butterfly, and we'll use puts because the strikes will all be out-of-the-money. This helps to reduce assignment risk.</p><p>With a regular butterfly option trade, the wings are placed an equal distance from the short strike, but with a broken wing butterfly we leave a larger gap on a particular side. This results in less risk on <a href=\"https://laohu8.com/S/AONE\">one</a> side and more risk on the opposite side.</p><h2>Netflix Stock Broken Wing Butterfly</h2><p>Let's take a look at how a broken wing butterfly trade might be set up on Netflix stock.</p><ul><li>Buy 1 June 18 475 put at 6.25</li><li>Sell 2 June 18 450 put at 2.60</li><li>Buy 1 June 18 400 put at 0.85</li></ul><p>Notice that the upper strike put is 25 points away from the middle put and the lower put is 50 points away. This broken wing butterfly trade will cost $190 to open, and this is the maximum risk on the upside.</p><p>The worst that can happen is all the puts expire worthless and the trade loses the $190 premium.</p><p>On the downside, the maximum loss can be calculated by taking the width between the first two strikes (25) multiplied by 100 and adding the premium paid (190).</p><p>That gives us 25 x 100 + 190 = $2,690.</p><p>The maximum gain can be calculated as 25 x 100 - 190 = $2,310</p><p>The ideal scenario for the trade is that Netflix stock stays flat initially and then slowly drifts lower to close around 450 at expiration. The total profit zone is between 427 and 472.</p><h2>Trade For Those With Bearish Outlook On Netflix Stock</h2><p>Because the trade starts with delta of -7, this strategy would not be appropriate for bullish traders. The initial exposure is roughly equivalent to being short seven shares of NFLX stock.</p><p>For those with a slightly bearish outlook, a broken wing butterfly could be a nice way to trade Netflix stock.</p><p>In terms of risk management, I would set a stop loss of 20% of the capital at risk (0.2 x $2,690 = $538), or if Netflix broke below 425.</p><p>It's important to remember that options are risky and investors can lose 100% of their investment.</p><p>This article is for education purposes only and not a trade recommendation. Remember to always do your own due diligence and consult your financial advisor before making any investment decisions.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Trading A Broken Wing Butterfly In Netflix Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTrading A Broken Wing Butterfly In Netflix Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Investors </p>\n<p class=\"h-time\">2021-05-24 23:08</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Netflix</b> stock is struggling to break above 500 and is currently below the 50- and 200-day moving averages.</p><p>Today, I want to look at a strategy with very low risk on the upside and a healthy profit zone on the downside.</p><p>The strategy is called a broken wing butterfly, and we'll use puts because the strikes will all be out-of-the-money. This helps to reduce assignment risk.</p><p>With a regular butterfly option trade, the wings are placed an equal distance from the short strike, but with a broken wing butterfly we leave a larger gap on a particular side. This results in less risk on <a href=\"https://laohu8.com/S/AONE\">one</a> side and more risk on the opposite side.</p><h2>Netflix Stock Broken Wing Butterfly</h2><p>Let's take a look at how a broken wing butterfly trade might be set up on Netflix stock.</p><ul><li>Buy 1 June 18 475 put at 6.25</li><li>Sell 2 June 18 450 put at 2.60</li><li>Buy 1 June 18 400 put at 0.85</li></ul><p>Notice that the upper strike put is 25 points away from the middle put and the lower put is 50 points away. This broken wing butterfly trade will cost $190 to open, and this is the maximum risk on the upside.</p><p>The worst that can happen is all the puts expire worthless and the trade loses the $190 premium.</p><p>On the downside, the maximum loss can be calculated by taking the width between the first two strikes (25) multiplied by 100 and adding the premium paid (190).</p><p>That gives us 25 x 100 + 190 = $2,690.</p><p>The maximum gain can be calculated as 25 x 100 - 190 = $2,310</p><p>The ideal scenario for the trade is that Netflix stock stays flat initially and then slowly drifts lower to close around 450 at expiration. The total profit zone is between 427 and 472.</p><h2>Trade For Those With Bearish Outlook On Netflix Stock</h2><p>Because the trade starts with delta of -7, this strategy would not be appropriate for bullish traders. The initial exposure is roughly equivalent to being short seven shares of NFLX stock.</p><p>For those with a slightly bearish outlook, a broken wing butterfly could be a nice way to trade Netflix stock.</p><p>In terms of risk management, I would set a stop loss of 20% of the capital at risk (0.2 x $2,690 = $538), or if Netflix broke below 425.</p><p>It's important to remember that options are risky and investors can lose 100% of their investment.</p><p>This article is for education purposes only and not a trade recommendation. Remember to always do your own due diligence and consult your financial advisor before making any investment decisions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"QNETCN":"纳斯达克中美互联网老虎指数","NFLX":"奈飞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2137155528","content_text":"Netflix stock is struggling to break above 500 and is currently below the 50- and 200-day moving averages.Today, I want to look at a strategy with very low risk on the upside and a healthy profit zone on the downside.The strategy is called a broken wing butterfly, and we'll use puts because the strikes will all be out-of-the-money. This helps to reduce assignment risk.With a regular butterfly option trade, the wings are placed an equal distance from the short strike, but with a broken wing butterfly we leave a larger gap on a particular side. This results in less risk on one side and more risk on the opposite side.Netflix Stock Broken Wing ButterflyLet's take a look at how a broken wing butterfly trade might be set up on Netflix stock.Buy 1 June 18 475 put at 6.25Sell 2 June 18 450 put at 2.60Buy 1 June 18 400 put at 0.85Notice that the upper strike put is 25 points away from the middle put and the lower put is 50 points away. This broken wing butterfly trade will cost $190 to open, and this is the maximum risk on the upside.The worst that can happen is all the puts expire worthless and the trade loses the $190 premium.On the downside, the maximum loss can be calculated by taking the width between the first two strikes (25) multiplied by 100 and adding the premium paid (190).That gives us 25 x 100 + 190 = $2,690.The maximum gain can be calculated as 25 x 100 - 190 = $2,310The ideal scenario for the trade is that Netflix stock stays flat initially and then slowly drifts lower to close around 450 at expiration. The total profit zone is between 427 and 472.Trade For Those With Bearish Outlook On Netflix StockBecause the trade starts with delta of -7, this strategy would not be appropriate for bullish traders. The initial exposure is roughly equivalent to being short seven shares of NFLX stock.For those with a slightly bearish outlook, a broken wing butterfly could be a nice way to trade Netflix stock.In terms of risk management, I would set a stop loss of 20% of the capital at risk (0.2 x $2,690 = $538), or if Netflix broke below 425.It's important to remember that options are risky and investors can lose 100% of their investment.This article is for education purposes only and not a trade recommendation. Remember to always do your own due diligence and consult your financial advisor before making any investment decisions.","news_type":1},"isVote":1,"tweetType":1,"viewCount":373,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":108094698,"gmtCreate":1619957154414,"gmtModify":1704336760147,"author":{"id":"3582539332868122","authorId":"3582539332868122","name":"ToMoonD","avatar":"https://static.tigerbbs.com/f92d4ac39ec4bc607230f926b9344276","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582539332868122","idStr":"3582539332868122"},"themes":[],"htmlText":"Like and comment pls","listText":"Like and comment pls","text":"Like and comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/108094698","repostId":"1142063705","repostType":4,"repost":{"id":"1142063705","pubTimestamp":1619796118,"share":"https://ttm.financial/m/news/1142063705?lang=&edition=fundamental","pubTime":"2021-04-30 23:21","market":"us","language":"en","title":"Europe's antitrust crackdown on Apple hints at what's coming for the company in the U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=1142063705","media":"CNBC","summary":"For a long time, the European Commission seemed to stand apart from the U.S. in cracking down on tech giants with antitrust fines againstGoogleand privacy rules like the General Data Protection Regulation.“The Commission’s argument onSpotify’sbehalf is the opposite of fair competition,” Apple said in a statement following Vestager’s announcement, referring to the music streaming company that raised the competition complaint. Apple said Spotify wants “all the benefits of the App Store but don’t t","content":"<div>\n<p>For a long time, the European Commission seemed to stand apart from the U.S. in cracking down on tech giants with antitrust fines againstGoogleand privacy rules like the General Data Protection ...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/30/eu-leads-tech-crackdown-but-the-us-isnt-far-behind.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Europe's antitrust crackdown on Apple hints at what's coming for the company in the U.S.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEurope's antitrust crackdown on Apple hints at what's coming for the company in the U.S.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-30 23:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/04/30/eu-leads-tech-crackdown-but-the-us-isnt-far-behind.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For a long time, the European Commission seemed to stand apart from the U.S. in cracking down on tech giants with antitrust fines againstGoogleand privacy rules like the General Data Protection ...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/30/eu-leads-tech-crackdown-but-the-us-isnt-far-behind.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.cnbc.com/2021/04/30/eu-leads-tech-crackdown-but-the-us-isnt-far-behind.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1142063705","content_text":"For a long time, the European Commission seemed to stand apart from the U.S. in cracking down on tech giants with antitrust fines againstGoogleand privacy rules like the General Data Protection Regulation.\nBut when the EU competition policy chief Margrethe Vestagerannounced Friday a preliminary findingthatApplehas abused its dominant power in the distribution of streaming music apps, the U.S. finally seems poised to move in a similar direction.\n“The Commission’s argument onSpotify’sbehalf is the opposite of fair competition,” Apple said in a statement following Vestager’s announcement, referring to the music streaming company that raised the competition complaint. Apple said Spotify wants “all the benefits of the App Store but don’t think they should have to pay anything for that,” by choosing to object to its 15-30% commission on in-app payments for streaming apps.\nApple isn’t currently facing any antitrust charges from government officials in the U.S. and such a lawsuit may never materialize, though the Department of Justice wasreportedly granted oversight of the company’s competitive practices in 2019. But even if the government declines to press charges, recent actions in Congress, state legislatures and in private lawsuits demonstrate a significant shift in the American public’s sentiment toward Apple and the tech industry at large.\nWhen the commissionslapped its first record competition fineagainstGooglein 2017, it wasn’t yet clear that the U.S. might be ready to move on from its once-cozy relationship with its booming tech industry. But in 2018, on the heels of the revelations of howFacebookuser data was used by analytics company Cambridge Analytica during the 2016 election, and increasing questions about how tech platforms can impact American democracy, that seemed to change.\nNow, as Europe continues to move forward with its probe into Apple, the U.S. no longer seems to be so far behind.\nHere’s where Apple stands to face risk of antitrust action or regulation in the U.S.:\nDOJ\nThe DOJ has already moved forward with a massive lawsuit against Google, so it could take some time if it decides to ramp up a probe into Apple. Though the DOJ’s Antitrust Division took on oversight authority of Apple in a 2019 agreement with the FTC, according to aWall Street Journal report, the Google investigation has seemed to take priority.\nStill, then-Attorney General Bill Barr announced later that year that the DOJ wouldconduct a broad antitrust review of Big Tech companies.\nAny action from the DOJ or state enforcers would take the form of a settlement or lawsuit, which would put Apple’s fate in the hands of the courts.\nPrivate lawsuits\nApple’s most immediate challenge in the U.S. has come from private companies bringing antitrust charges against its business in court.\nThe most notable of these lawsuits isfrom Fortnite-maker Epic Games, which is set to begin its trial on Monday. Epic filed its lawsuit with a PR blitz afterchallenging Apple’s in-app payment feeby advertising in its app an alternative, cheaper way to buy character outfits from Epic directly, violating Apple’s rules. That prompted Apple to remove Fortnite from its App Store. Epic filed the suit shortly after and Applefiled counterclaimsagainst Epic for allegedly breaching its contract.\n“Although Epic portrays itself as a modern corporate Robin Hood, in reality it is a multi-billion dollar enterprise that simply wants to pay nothing for the tremendous value it derives from the App Store,” Apple said in a filing with the District Court for the Northern District of California in September.\nCongress\nJust last week,several app-makers testified before the Senate Judiciary subcommittee on antitrust about the alleged anti-competitive harms they’ve facedfrom restrictions on both Apple and Google’s app stores.\nRepresentatives from Apple and Google told lawmakers they simply charge for the technology and the work they put into running the app stores, which have significantly lowered distribution costs for app developers over the years.\nBut witnesses from Tinder-ownerMatch Group, item-tracking device-maker Tile and Spotify painted a different picture.\n“We’re all afraid,” Match Group chief legal officer Jared Sine testified of the platforms’ broad power over their businesses.\nThe witnesses discussed the seemingly arbitrary nature by which Apple allegedly enforces its App Store rules. Spotify’s legal chief claimed Apple has threatened retaliation on numerous occasions and Tile’s top lawyer said Apple denied access to a key feature that wouldimprove their object-tracking product, before utilizing it for Apple’s own rival gadget,called AirTag.\nTile said that while Apple now makes the feature available for third-party developers to incorporate, accessing it would mean handing over a significant amount of data and control to Apple. Apple’s representative said its product is different from Tile’s and opening the feature in question will encourage further competition in the space.\nSenators at the hearing seemed receptive to the app developers’ complaints, which build on earlier claims made before House lawmakers. The House Judiciary subcommittee on antitrust found in a more than year-long probe thatAmazon, Apple, Facebook and Googleall hold monopoly power, and lawmakers are currently crafting bills to enable stronger antitrust enforcement of digital markets.\nState Legislatures\nSeveral state legislatures have beenconsidering bills that would require platforms like Apple and Google to allow app-makers to use their own payment processing systems. While the bills have so far hadvarying degrees of successin the early stages of lawmaking, passage in one state could raise a host of questions about how it should be enforced given the ambiguous nature of digital borders.\nThe bills have been supported by the Coalition for App Fairness, a group of companies that have complained about app store fees, including Epic Games, Match Group and Spotify.\nApple has often argued that it maintains features like payments within its own ecosystem in order to protect consumers and secure their data, though app developers and lawmakers have expressed skepticism about that reasoning.","news_type":1},"isVote":1,"tweetType":1,"viewCount":126,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":127915644,"gmtCreate":1624813880788,"gmtModify":1703845481769,"author":{"id":"3582539332868122","authorId":"3582539332868122","name":"ToMoonD","avatar":"https://static.tigerbbs.com/f92d4ac39ec4bc607230f926b9344276","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582539332868122","idStr":"3582539332868122"},"themes":[],"htmlText":"Shuhshsjddds","listText":"Shuhshsjddds","text":"Shuhshsjddds","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/127915644","repostId":"2146090006","repostType":4,"repost":{"id":"2146090006","pubTimestamp":1624755315,"share":"https://ttm.financial/m/news/2146090006?lang=&edition=fundamental","pubTime":"2021-06-27 08:55","market":"us","language":"en","title":"5 Buffett Stocks to Buy Hand Over Fist for the Second Half of 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=2146090006","media":"Motley Fool","summary":"These growth and value stocks are begging to be bought by investors.","content":"<p>When Warren Buffett buys or sells a stock, Wall Street and retail investors tend to pay very close attention. That's because the Oracle of Omaha's track record is virtually unsurpassed. Since taking the reins of <b>Berkshire Hathaway</b> (NYSE:BRK.A)(NYSE:BRK.B) in the mid-1960s, Buffett's company has averaged an annual return of 20%. This works out to an aggregate gain of greater than 2,800,000% for its Class A shares.</p>\n<p>Although Buffett isn't perfect, he and his investing team have a knack for identifying attractively valued businesses that have clear competitive advantages. As we prepare to move into the second half of 2021, the following five Buffett stocks stand out as those that should be bought hand over fist.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1077c8372814d2b8150e933b4c608005\" tg-width=\"700\" tg-height=\"466\"><span>Berkshire Hathaway CEO Warren Buffett. Image source: The Motley Fool.</span></p>\n<h2>Amazon</h2>\n<p>Even though Buffett's investing lieutenants, Todd Combs and Ted Weschler, are the architects behind Berkshire Hathaway's stake in <b>Amazon</b> (NASDAQ:AMZN), it's arguably the Buffett stock that should be bought most aggressively ahead of the second half of the year.</p>\n<p>As most folks probably know, Amazon is an e-commerce juggernaut. Based on an April report from eMarketer, the company effectively controls $0.40 of every $1 spent online in the United States. It's also pivoted its online retail popularity into signing up more than 200 million people to its Prime program worldwide. The fees Amazon collects from Prime help it to undercut its competition on price. And it certainly doesn't hurt that Prime members tend to spend many multiples more than non-Prime shoppers during the course of the year.</p>\n<p>But it's the company's cloud infrastructure service, Amazon Web Services (AWS), that has truly budded into a star. Since the operating margins associated with cloud infrastructure are considerably higher than what Amazon nets from retail and advertising, AWS' growth is leading to a surge in operating cash flow. If investors were to continue to pay the midpoint of Amazon's operating cash flow multiple over the past decade, it could hit $10,000 a share by 2025.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b18b49b2b35da2fc49e0a83b883d1c22\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Bristol Myers Squibb</h2>\n<p>Pharmaceutical stocks are money machines, and none looks to be more attractive on a valuation basis than <b>Bristol Myers Squibb</b> (NYSE:BMY).</p>\n<p>One reason to be excited about this drug developer is its organic growth potential. Eliquis, which was co-developed with <b>Pfizer</b>, has blossomed into the world's leading oral anticoagulant, with sales expected to surpass $10 billion in 2021. Meanwhile, dozens of additional clinical trials are underway for cancer immunotherapy Opdivo, which generated $7 billion in sales last year. This offers plenty of opportunity to expand Opdivo's label and pump up its pricing power.</p>\n<p>Another reason Bristol Myers Squibb is such an intriguing stock is its November 2019 acquisition of cancer and immunology company Celgene. Buying Celgene brought the blockbuster multiple-myeloma drug Revlimid into the fold. Revlimid has sustainably grown its annual sales by a double-digit percentage for more than a decade, with label expansion, longer duration of use, and pricing power all playing a role. This key treatment, which topped $12 billion in sales last year, is protected from a full onslaught of generic competition until early 2026. That means Bristol Myers will be rolling in the dough for another five years, at minimum.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1b152e369d7c967dcbc926192ee888c1\" tg-width=\"700\" tg-height=\"531\"><span>Image source: Getty Images.</span></p>\n<h2>Mastercard</h2>\n<p>Everyone seems to be looking for the smartest recovery play from the pandemic. Payment processor <b>Mastercard</b> (NYSE:MA) might well be the safest way to take advantage of a steady uptick in consumer and enterprise spending.</p>\n<p>Mastercard isn't a cheap stock by any means -- at 36 times Wall Street's forward-year earnings consensus -- but it benefits from a simple numbers game. While economic contractions and recessions are inevitable, these periods of turbulence tend to be short-lived. By comparison, economic expansions often last many years. Buying into Mastercard allows investors to take full advantage of these long periods of economic expansion and robust spending. Plus, it doesn't hurt that Mastercard has the second-highest share of credit-card network purchase volume in the U.S., the leading market for consumption.</p>\n<p>Investors can also sleep easy with the understanding that Mastercard strictly sticks to payment facilitation. Even though some of its peers also lend, and are therefore able to generate interest income and fees during bull markets, Mastercard has avoided becoming a lender. It's something you'll truly appreciate when a recession strikes. Whereas most financial stocks will be forced to set aside capital to cover credit or loan delinquencies, Mastercard won't have to. This is a big reason it bounces back from recessions quicker than most financial stocks.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e4e1a1fe028efa4c966b66ef2cd466f5\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Teva Pharmaceutical Industries</h2>\n<p>If you have an appetite for turnaround plays, brand-name and generic-drug developer <b>Teva Pharmaceutical Industries</b> (NYSE:TEVA) is the stock to buy hand over fist for the second half of 2021. Like Amazon, it's a stock that was added to Berkshire Hathaway's portfolio by either Combs or Weschler and not Buffett.</p>\n<p>While there's no denying that Teva has its fair share of hurdles to overcome, the company's turnaround-focused CEO, Kare Schultz, has been a blessing. Since taking the helm less than four years ago, Schultz has helped shave off more than $10 billion in net debt, and he's overseen the reduction of roughly $3 billion in annual operating expenses. There's more work to do to improve Teva's balance sheet, but the company is very clearly on much firmer ground than it was back in 2016-2017.</p>\n<p>Schultz also has the potential to play peacemaker for a number of outstanding lawsuits targeting Teva's role in the opioid crisis. If this litigation can be resolved with minimal cash outlay, Teva's valuation could soar. At just 4 times the company's projected earnings in 2021, Teva is about as cheap as a healthcare stock can get.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/44a30c4dfd6886a29e22d3c6558c3e56\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Bank of America</h2>\n<p>Lastly, bank stock <b>Bank of America</b> (NYSE:BAC) has the look of a company that can be confidently bought hand over fist for the second half of 2021.</p>\n<p>For much of the past decade, the Federal Reserve has kept interest rates at or near historic lows. That's meant less in the way of interest income for banks. But the latest update from the nation's central bank suggests that interest rates could begin creeping up in 2023, a year earlier than previously forecast. Bank of America is the most interest-sensitive money-center bank. According to its first-quarter investor presentation, BofA would generate $8.3 billion in net interest income on a 100-basis-point shift in the interest rate yield curve. Translation: Bank of America's profits should rocket higher beginning in 2023-2024.</p>\n<p>At the same time, BofA has done an outstanding job of controlling its costs and improving its operating efficiency. Investments in digitization have resulted in higher mobile app and digital banking use, which is allowing the company to consolidate some of its branches. Even with its shares at a 13-year high, Bank of America has plenty left in the tank.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Buffett Stocks to Buy Hand Over Fist for the Second Half of 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Buffett Stocks to Buy Hand Over Fist for the Second Half of 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-27 08:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/26/buffett-stocks-buy-hand-over-fist-second-half-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When Warren Buffett buys or sells a stock, Wall Street and retail investors tend to pay very close attention. That's because the Oracle of Omaha's track record is virtually unsurpassed. Since taking ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/26/buffett-stocks-buy-hand-over-fist-second-half-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BAC":"美国银行","AMZN":"亚马逊","BRK.A":"伯克希尔","TEVA":"梯瓦制药","BRK.B":"伯克希尔B","BMY":"施贵宝","MA":"万事达"},"source_url":"https://www.fool.com/investing/2021/06/26/buffett-stocks-buy-hand-over-fist-second-half-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146090006","content_text":"When Warren Buffett buys or sells a stock, Wall Street and retail investors tend to pay very close attention. That's because the Oracle of Omaha's track record is virtually unsurpassed. Since taking the reins of Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B) in the mid-1960s, Buffett's company has averaged an annual return of 20%. This works out to an aggregate gain of greater than 2,800,000% for its Class A shares.\nAlthough Buffett isn't perfect, he and his investing team have a knack for identifying attractively valued businesses that have clear competitive advantages. As we prepare to move into the second half of 2021, the following five Buffett stocks stand out as those that should be bought hand over fist.\nBerkshire Hathaway CEO Warren Buffett. Image source: The Motley Fool.\nAmazon\nEven though Buffett's investing lieutenants, Todd Combs and Ted Weschler, are the architects behind Berkshire Hathaway's stake in Amazon (NASDAQ:AMZN), it's arguably the Buffett stock that should be bought most aggressively ahead of the second half of the year.\nAs most folks probably know, Amazon is an e-commerce juggernaut. Based on an April report from eMarketer, the company effectively controls $0.40 of every $1 spent online in the United States. It's also pivoted its online retail popularity into signing up more than 200 million people to its Prime program worldwide. The fees Amazon collects from Prime help it to undercut its competition on price. And it certainly doesn't hurt that Prime members tend to spend many multiples more than non-Prime shoppers during the course of the year.\nBut it's the company's cloud infrastructure service, Amazon Web Services (AWS), that has truly budded into a star. Since the operating margins associated with cloud infrastructure are considerably higher than what Amazon nets from retail and advertising, AWS' growth is leading to a surge in operating cash flow. If investors were to continue to pay the midpoint of Amazon's operating cash flow multiple over the past decade, it could hit $10,000 a share by 2025.\nImage source: Getty Images.\nBristol Myers Squibb\nPharmaceutical stocks are money machines, and none looks to be more attractive on a valuation basis than Bristol Myers Squibb (NYSE:BMY).\nOne reason to be excited about this drug developer is its organic growth potential. Eliquis, which was co-developed with Pfizer, has blossomed into the world's leading oral anticoagulant, with sales expected to surpass $10 billion in 2021. Meanwhile, dozens of additional clinical trials are underway for cancer immunotherapy Opdivo, which generated $7 billion in sales last year. This offers plenty of opportunity to expand Opdivo's label and pump up its pricing power.\nAnother reason Bristol Myers Squibb is such an intriguing stock is its November 2019 acquisition of cancer and immunology company Celgene. Buying Celgene brought the blockbuster multiple-myeloma drug Revlimid into the fold. Revlimid has sustainably grown its annual sales by a double-digit percentage for more than a decade, with label expansion, longer duration of use, and pricing power all playing a role. This key treatment, which topped $12 billion in sales last year, is protected from a full onslaught of generic competition until early 2026. That means Bristol Myers will be rolling in the dough for another five years, at minimum.\nImage source: Getty Images.\nMastercard\nEveryone seems to be looking for the smartest recovery play from the pandemic. Payment processor Mastercard (NYSE:MA) might well be the safest way to take advantage of a steady uptick in consumer and enterprise spending.\nMastercard isn't a cheap stock by any means -- at 36 times Wall Street's forward-year earnings consensus -- but it benefits from a simple numbers game. While economic contractions and recessions are inevitable, these periods of turbulence tend to be short-lived. By comparison, economic expansions often last many years. Buying into Mastercard allows investors to take full advantage of these long periods of economic expansion and robust spending. Plus, it doesn't hurt that Mastercard has the second-highest share of credit-card network purchase volume in the U.S., the leading market for consumption.\nInvestors can also sleep easy with the understanding that Mastercard strictly sticks to payment facilitation. Even though some of its peers also lend, and are therefore able to generate interest income and fees during bull markets, Mastercard has avoided becoming a lender. It's something you'll truly appreciate when a recession strikes. Whereas most financial stocks will be forced to set aside capital to cover credit or loan delinquencies, Mastercard won't have to. This is a big reason it bounces back from recessions quicker than most financial stocks.\nImage source: Getty Images.\nTeva Pharmaceutical Industries\nIf you have an appetite for turnaround plays, brand-name and generic-drug developer Teva Pharmaceutical Industries (NYSE:TEVA) is the stock to buy hand over fist for the second half of 2021. Like Amazon, it's a stock that was added to Berkshire Hathaway's portfolio by either Combs or Weschler and not Buffett.\nWhile there's no denying that Teva has its fair share of hurdles to overcome, the company's turnaround-focused CEO, Kare Schultz, has been a blessing. Since taking the helm less than four years ago, Schultz has helped shave off more than $10 billion in net debt, and he's overseen the reduction of roughly $3 billion in annual operating expenses. There's more work to do to improve Teva's balance sheet, but the company is very clearly on much firmer ground than it was back in 2016-2017.\nSchultz also has the potential to play peacemaker for a number of outstanding lawsuits targeting Teva's role in the opioid crisis. If this litigation can be resolved with minimal cash outlay, Teva's valuation could soar. At just 4 times the company's projected earnings in 2021, Teva is about as cheap as a healthcare stock can get.\nImage source: Getty Images.\nBank of America\nLastly, bank stock Bank of America (NYSE:BAC) has the look of a company that can be confidently bought hand over fist for the second half of 2021.\nFor much of the past decade, the Federal Reserve has kept interest rates at or near historic lows. That's meant less in the way of interest income for banks. But the latest update from the nation's central bank suggests that interest rates could begin creeping up in 2023, a year earlier than previously forecast. Bank of America is the most interest-sensitive money-center bank. According to its first-quarter investor presentation, BofA would generate $8.3 billion in net interest income on a 100-basis-point shift in the interest rate yield curve. Translation: Bank of America's profits should rocket higher beginning in 2023-2024.\nAt the same time, BofA has done an outstanding job of controlling its costs and improving its operating efficiency. Investments in digitization have resulted in higher mobile app and digital banking use, which is allowing the company to consolidate some of its branches. Even with its shares at a 13-year high, Bank of America has plenty left in the tank.","news_type":1},"isVote":1,"tweetType":1,"viewCount":187,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":197001601,"gmtCreate":1621406897003,"gmtModify":1704357118878,"author":{"id":"3582539332868122","authorId":"3582539332868122","name":"ToMoonD","avatar":"https://static.tigerbbs.com/f92d4ac39ec4bc607230f926b9344276","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582539332868122","idStr":"3582539332868122"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MNMD\">$Mind Medicine (MindMed) Inc.(MNMD)$</a>Sad day","listText":"<a href=\"https://laohu8.com/S/MNMD\">$Mind Medicine (MindMed) Inc.(MNMD)$</a>Sad day","text":"$Mind Medicine (MindMed) Inc.(MNMD)$Sad day","images":[{"img":"https://static.tigerbbs.com/0adeb58019d90281e26a09c7a759cdcb","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/197001601","isVote":1,"tweetType":1,"viewCount":198,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":192877066,"gmtCreate":1621199454555,"gmtModify":1704353717289,"author":{"id":"3582539332868122","authorId":"3582539332868122","name":"ToMoonD","avatar":"https://static.tigerbbs.com/f92d4ac39ec4bc607230f926b9344276","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582539332868122","idStr":"3582539332868122"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MNMD\">$Mind Medicine (MindMed) Inc.(MNMD)$</a>sad butlet’s ho","listText":"<a href=\"https://laohu8.com/S/MNMD\">$Mind Medicine (MindMed) Inc.(MNMD)$</a>sad butlet’s ho","text":"$Mind Medicine (MindMed) Inc.(MNMD)$sad butlet’s ho","images":[{"img":"https://static.tigerbbs.com/b4d694095f0f203aacb0862520ae1d33","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/192877066","isVote":1,"tweetType":1,"viewCount":146,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":106526581,"gmtCreate":1620135568443,"gmtModify":1704339118528,"author":{"id":"3582539332868122","authorId":"3582539332868122","name":"ToMoonD","avatar":"https://static.tigerbbs.com/f92d4ac39ec4bc607230f926b9344276","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582539332868122","idStr":"3582539332868122"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MNMD\">$Mind Medicine (MindMed) Inc.(MNMD)$</a>Down bad","listText":"<a href=\"https://laohu8.com/S/MNMD\">$Mind Medicine (MindMed) Inc.(MNMD)$</a>Down bad","text":"$Mind Medicine (MindMed) Inc.(MNMD)$Down bad","images":[{"img":"https://static.tigerbbs.com/bfd355bb2a75d7e5f1fcf6a801018da9","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/106526581","isVote":1,"tweetType":1,"viewCount":256,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":106528564,"gmtCreate":1620135532558,"gmtModify":1704339117561,"author":{"id":"3582539332868122","authorId":"3582539332868122","name":"ToMoonD","avatar":"https://static.tigerbbs.com/f92d4ac39ec4bc607230f926b9344276","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582539332868122","idStr":"3582539332868122"},"themes":[],"htmlText":"Testing like and comment","listText":"Testing like and comment","text":"Testing like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/106528564","repostId":"1142616846","repostType":4,"isVote":1,"tweetType":1,"viewCount":120,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":159656371,"gmtCreate":1624965340293,"gmtModify":1703848953189,"author":{"id":"3582539332868122","authorId":"3582539332868122","name":"ToMoonD","avatar":"https://static.tigerbbs.com/f92d4ac39ec4bc607230f926b9344276","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582539332868122","idStr":"3582539332868122"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MNMD\">$Mind Medicine (MindMed) Inc.(MNMD)$</a>Hdshehejd","listText":"<a href=\"https://laohu8.com/S/MNMD\">$Mind Medicine (MindMed) Inc.(MNMD)$</a>Hdshehejd","text":"$Mind Medicine (MindMed) Inc.(MNMD)$Hdshehejd","images":[{"img":"https://static.tigerbbs.com/736086d0bcbf7e1764bfe6d178fabf46","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/159656371","isVote":1,"tweetType":1,"viewCount":277,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":124317376,"gmtCreate":1624739167495,"gmtModify":1703844219362,"author":{"id":"3582539332868122","authorId":"3582539332868122","name":"ToMoonD","avatar":"https://static.tigerbbs.com/f92d4ac39ec4bc607230f926b9344276","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582539332868122","idStr":"3582539332868122"},"themes":[],"htmlText":"Ok nice&nbsp;","listText":"Ok nice&nbsp;","text":"Ok nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/124317376","repostId":"2146500392","repostType":4,"isVote":1,"tweetType":1,"viewCount":106,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":136241816,"gmtCreate":1622023570035,"gmtModify":1704366265877,"author":{"id":"3582539332868122","authorId":"3582539332868122","name":"ToMoonD","avatar":"https://static.tigerbbs.com/f92d4ac39ec4bc607230f926b9344276","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582539332868122","idStr":"3582539332868122"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MNMD\">$Mind Medicine (MindMed) Inc.(MNMD)$</a>Nice hello","listText":"<a href=\"https://laohu8.com/S/MNMD\">$Mind Medicine (MindMed) Inc.(MNMD)$</a>Nice hello","text":"$Mind Medicine (MindMed) Inc.(MNMD)$Nice hello","images":[{"img":"https://static.tigerbbs.com/5b375c29ff52da1b3f7167a2ac49dc26","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/136241816","isVote":1,"tweetType":1,"viewCount":259,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":131440319,"gmtCreate":1621883692531,"gmtModify":1704363782069,"author":{"id":"3582539332868122","authorId":"3582539332868122","name":"ToMoonD","avatar":"https://static.tigerbbs.com/f92d4ac39ec4bc607230f926b9344276","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582539332868122","idStr":"3582539332868122"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MNMD\">$Mind Medicine (MindMed) Inc.(MNMD)$</a>Hahahahaha","listText":"<a href=\"https://laohu8.com/S/MNMD\">$Mind Medicine (MindMed) Inc.(MNMD)$</a>Hahahahaha","text":"$Mind Medicine (MindMed) Inc.(MNMD)$Hahahahaha","images":[{"img":"https://static.tigerbbs.com/a72d5416da78f84c5ac4e18f474e6c4d","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/131440319","isVote":1,"tweetType":1,"viewCount":173,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":106526036,"gmtCreate":1620135544725,"gmtModify":1704339117883,"author":{"id":"3582539332868122","authorId":"3582539332868122","name":"ToMoonD","avatar":"https://static.tigerbbs.com/f92d4ac39ec4bc607230f926b9344276","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582539332868122","idStr":"3582539332868122"},"themes":[],"htmlText":"Nice etf index","listText":"Nice etf index","text":"Nice etf index","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/106526036","repostId":"1119128956","repostType":4,"repost":{"id":"1119128956","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1620132952,"share":"https://ttm.financial/m/news/1119128956?lang=&edition=fundamental","pubTime":"2021-05-04 20:55","market":"us","language":"en","title":"S&P Launches Bitcoin, Ethereum, Crypto Mega Cap Indexes","url":"https://stock-news.laohu8.com/highlight/detail?id=1119128956","media":"Benzinga","summary":"S&P Dow Jones Indices launched its first three crypto indexes on Monday, according to areportfrom Co","content":"<p>S&amp;P Dow Jones Indices launched its first three crypto indexes on Monday, according to areportfrom CoinDesk.</p>\n<p><b>What Happened:</b>&nbsp;The three indexes will measure the performance of digital assets listed on registered open exchanges.</p>\n<p>TheS&amp;P Bitcoin Index(SPBTC) tracks the performance of the leading digital asset<b>Bitcoin</b>(CRYPTO: BTC), while theS&amp;P Ethereum Index(SPETH) tracks the performance of the second-largest cryptocurrency by market cap,<b>Ethereum</b>(CRYPTO: ETH).</p>\n<p>S&amp;P also included a third crypto index,&nbsp;theS&amp;P Crypto Mega Cap Index(SPCMC) which tracks the performance of both Bitcoin and Ethereum together.</p>\n<p>New York-based cryptocurrency data firm Lukka provided the “world's first fair market value-focused” pricing methodology to price the S&amp;P indexes.</p>\n<p>This method of valuation is designed to align the crypto ecosystem to GAAP and IFRS guidelines, according to the indexes’methodology document.</p>\n<p><b>Why It Matters:</b>&nbsp;Since the indexes measure price appreciation and not the current price of the underlying asset, comparing the two indices helps traders make an easy assessment of the better-performing asset over time.</p>\n<p>For instance, at the time of writing the index showed that Bitcoin’s return over a one-year period was 558% as opposed to Ethereum’s one-year return, which was 1,477%.</p>\n<p>\"With digital assets such as cryptocurrencies becoming a rapidly emerging asset class, the time is right for independent, reliable, and user-friendly benchmarks. We're excited to work with Lukka, who has been at the forefront of digital asset data services, to promote more transparency in this nascent sector,\"&nbsp;saidPeter Roffman, global head of innovation and strategy at S&amp;P Dow Jones Indices.</p>\n<p>S&amp;P’s crypto index comes in addition to the existing digital asset indexeslaunchednearly three years ago by Bloomberg and Galaxy Digital Capital Management.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S&P Launches Bitcoin, Ethereum, Crypto Mega Cap Indexes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS&P Launches Bitcoin, Ethereum, Crypto Mega Cap Indexes\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-05-04 20:55</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>S&amp;P Dow Jones Indices launched its first three crypto indexes on Monday, according to areportfrom CoinDesk.</p>\n<p><b>What Happened:</b>&nbsp;The three indexes will measure the performance of digital assets listed on registered open exchanges.</p>\n<p>TheS&amp;P Bitcoin Index(SPBTC) tracks the performance of the leading digital asset<b>Bitcoin</b>(CRYPTO: BTC), while theS&amp;P Ethereum Index(SPETH) tracks the performance of the second-largest cryptocurrency by market cap,<b>Ethereum</b>(CRYPTO: ETH).</p>\n<p>S&amp;P also included a third crypto index,&nbsp;theS&amp;P Crypto Mega Cap Index(SPCMC) which tracks the performance of both Bitcoin and Ethereum together.</p>\n<p>New York-based cryptocurrency data firm Lukka provided the “world's first fair market value-focused” pricing methodology to price the S&amp;P indexes.</p>\n<p>This method of valuation is designed to align the crypto ecosystem to GAAP and IFRS guidelines, according to the indexes’methodology document.</p>\n<p><b>Why It Matters:</b>&nbsp;Since the indexes measure price appreciation and not the current price of the underlying asset, comparing the two indices helps traders make an easy assessment of the better-performing asset over time.</p>\n<p>For instance, at the time of writing the index showed that Bitcoin’s return over a one-year period was 558% as opposed to Ethereum’s one-year return, which was 1,477%.</p>\n<p>\"With digital assets such as cryptocurrencies becoming a rapidly emerging asset class, the time is right for independent, reliable, and user-friendly benchmarks. We're excited to work with Lukka, who has been at the forefront of digital asset data services, to promote more transparency in this nascent sector,\"&nbsp;saidPeter Roffman, global head of innovation and strategy at S&amp;P Dow Jones Indices.</p>\n<p>S&amp;P’s crypto index comes in addition to the existing digital asset indexeslaunchednearly three years ago by Bloomberg and Galaxy Digital Capital Management.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1119128956","content_text":"S&P Dow Jones Indices launched its first three crypto indexes on Monday, according to areportfrom CoinDesk.\nWhat Happened: The three indexes will measure the performance of digital assets listed on registered open exchanges.\nTheS&P Bitcoin Index(SPBTC) tracks the performance of the leading digital assetBitcoin(CRYPTO: BTC), while theS&P Ethereum Index(SPETH) tracks the performance of the second-largest cryptocurrency by market cap,Ethereum(CRYPTO: ETH).\nS&P also included a third crypto index, theS&P Crypto Mega Cap Index(SPCMC) which tracks the performance of both Bitcoin and Ethereum together.\nNew York-based cryptocurrency data firm Lukka provided the “world's first fair market value-focused” pricing methodology to price the S&P indexes.\nThis method of valuation is designed to align the crypto ecosystem to GAAP and IFRS guidelines, according to the indexes’methodology document.\nWhy It Matters: Since the indexes measure price appreciation and not the current price of the underlying asset, comparing the two indices helps traders make an easy assessment of the better-performing asset over time.\nFor instance, at the time of writing the index showed that Bitcoin’s return over a one-year period was 558% as opposed to Ethereum’s one-year return, which was 1,477%.\n\"With digital assets such as cryptocurrencies becoming a rapidly emerging asset class, the time is right for independent, reliable, and user-friendly benchmarks. We're excited to work with Lukka, who has been at the forefront of digital asset data services, to promote more transparency in this nascent sector,\" saidPeter Roffman, global head of innovation and strategy at S&P Dow Jones Indices.\nS&P’s crypto index comes in addition to the existing digital asset indexeslaunchednearly three years ago by Bloomberg and Galaxy Digital Capital Management.","news_type":1},"isVote":1,"tweetType":1,"viewCount":179,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":108285435,"gmtCreate":1620030964427,"gmtModify":1704337604164,"author":{"id":"3582539332868122","authorId":"3582539332868122","name":"ToMoonD","avatar":"https://static.tigerbbs.com/f92d4ac39ec4bc607230f926b9344276","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582539332868122","idStr":"3582539332868122"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MNMD\">$Mind Medicine (MindMed) Inc.(MNMD)$</a> :(","listText":"<a href=\"https://laohu8.com/S/MNMD\">$Mind Medicine (MindMed) Inc.(MNMD)$</a> :(","text":"$Mind Medicine (MindMed) Inc.(MNMD)$ :(","images":[{"img":"https://static.tigerbbs.com/d603ebf62794b043beb59af4749910cc","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/108285435","isVote":1,"tweetType":1,"viewCount":176,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":108097930,"gmtCreate":1619957242720,"gmtModify":1704336761139,"author":{"id":"3582539332868122","authorId":"3582539332868122","name":"ToMoonD","avatar":"https://static.tigerbbs.com/f92d4ac39ec4bc607230f926b9344276","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582539332868122","idStr":"3582539332868122"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MNMD\">$Mind Medicine (MindMed) Inc.(MNMD)$</a> Sad :(","listText":"<a href=\"https://laohu8.com/S/MNMD\">$Mind Medicine (MindMed) Inc.(MNMD)$</a> Sad :(","text":"$Mind Medicine (MindMed) Inc.(MNMD)$ Sad :(","images":[{"img":"https://static.tigerbbs.com/8bfb057105b578bc88e390787d845a09","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/108097930","isVote":1,"tweetType":1,"viewCount":144,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":109442935,"gmtCreate":1619713162727,"gmtModify":1704271299614,"author":{"id":"3582539332868122","authorId":"3582539332868122","name":"ToMoonD","avatar":"https://static.tigerbbs.com/f92d4ac39ec4bc607230f926b9344276","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582539332868122","idStr":"3582539332868122"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MNMD\">$Mind Medicine (MindMed) Inc.(MNMD)$</a>:(","listText":"<a href=\"https://laohu8.com/S/MNMD\">$Mind Medicine (MindMed) Inc.(MNMD)$</a>:(","text":"$Mind Medicine (MindMed) Inc.(MNMD)$:(","images":[{"img":"https://static.tigerbbs.com/697fc87429200e4822fe9f3b20cf206f","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/109442935","isVote":1,"tweetType":1,"viewCount":332,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":129055340,"gmtCreate":1624347013980,"gmtModify":1703834071003,"author":{"id":"3582539332868122","authorId":"3582539332868122","name":"ToMoonD","avatar":"https://static.tigerbbs.com/f92d4ac39ec4bc607230f926b9344276","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582539332868122","idStr":"3582539332868122"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MNMD\">$Mind Medicine (MindMed) Inc.(MNMD)$</a>Nooo let’s ho","listText":"<a href=\"https://laohu8.com/S/MNMD\">$Mind Medicine (MindMed) Inc.(MNMD)$</a>Nooo let’s ho","text":"$Mind Medicine (MindMed) Inc.(MNMD)$Nooo let’s ho","images":[{"img":"https://static.tigerbbs.com/fb9c8ac3190a0450cce2ae42d63c8b30","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/129055340","isVote":1,"tweetType":1,"viewCount":286,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":136241532,"gmtCreate":1622023596126,"gmtModify":1704366266040,"author":{"id":"3582539332868122","authorId":"3582539332868122","name":"ToMoonD","avatar":"https://static.tigerbbs.com/f92d4ac39ec4bc607230f926b9344276","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582539332868122","idStr":"3582539332868122"},"themes":[],"htmlText":"Hdkeold","listText":"Hdkeold","text":"Hdkeold","images":[{"img":"https://static.tigerbbs.com/35e4d3488831a5a278323843446e2244","width":"750","height":"2162"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/136241532","isVote":1,"tweetType":1,"viewCount":175,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":133420535,"gmtCreate":1621785110627,"gmtModify":1704362395934,"author":{"id":"3582539332868122","authorId":"3582539332868122","name":"ToMoonD","avatar":"https://static.tigerbbs.com/f92d4ac39ec4bc607230f926b9344276","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582539332868122","idStr":"3582539332868122"},"themes":[],"htmlText":"Txt txt t&nbsp;","listText":"Txt txt t&nbsp;","text":"Txt txt t","images":[{"img":"https://static.tigerbbs.com/27d01dd0a09a2717b299a7ff8df6c24e","width":"750","height":"2053"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/133420535","isVote":1,"tweetType":1,"viewCount":262,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"lives":[]}